#United States #St. Louis #Diabetes Care #Lifestyle Medicine #Medication Deprescribing

New Study on Deprescribing Diabetes Medications

A recent research publication by the American College of Lifestyle Medicine presents compelling evidence on the safe and feasible reduction of diabetes medications through the incorporation of lifestyle medicine in primary care settings. This groundbreaking study, featured in the Journal of Clinical Medicine, delves into electronic health records from 650 adults with type 2 diabetes who were treated at two primary care practices that implement lifestyle medicine principles.

The investigation utilized a structured framework to assess deprescribing, identifying 41 confirmed instances where glucose-lowering medications were reduced or discontinued, impacting approximately 6.3% of the patient population observed. Notably, this deprescribing was achieved during standard routine care visits rather than specialized interventions, highlighting the potential for broader application in primary care environments.

Although a 6.3% medication reduction may seem modest, researchers emphasize the implications of such outcomes if replicated across the 38 million Americans living with type 2 diabetes. A seemingly small rate of deprescribing could lead to millions of individuals being able to lessen their medication intake, lower associated healthcare costs, and diminish the risk of side effects stemming from long-term medication use.

Dr. Gia Merlo, a professor at NYU Grossman School of Medicine, underscored the significance of these findings, suggesting that integrating lifestyle medicine into regular patient care can lead to meaningful, patient-centered results regarding medication reduction. The outcomes observed in patients who had their medications deprescribed were clinically meaningful, showing an average body mass index (BMI) decrease of 2.2 kg/m² and a drop in average blood glucose levels by 50.5 mg/dL—both statistically significant changes.

Among the medications that underwent adjustments, metformin saw a reduction in dosage by 34%, with discontinuation rates reaching 19.5%. Insulin doses were also cut down by 19.5%. Importantly, the analysis noted three adverse events during the review process; however, none were linked to the deprescribing measures applied within the lifestyle-focused primary care framework.

Interestingly, lifestyle changes were documented in just over half of the cases where medication was reduced—most frequently through dietary modifications and increased physical activity. Researchers caution that this finding may underestimate the true level of lifestyle engagement among patients, pointing to potential documentation shortcomings as a variable.

Looking ahead, the study advocates for continued research to explore the outcomes of deprescribing following lifestyle-informed care. Micaela C. Karlsen, a senior director at ACLM, emphasizes that adopting deprescribing protocols attuned to lifestyle-driven improvements presents an opportunity to enhance patient-centered, evidence-based care models for chronic diseases.

About the American College of Lifestyle Medicine (ACLM)

The American College of Lifestyle Medicine is a leading organization advocating for lifestyle medicine as a core component of a revisited, value-based healthcare system. ACLM equips its members with knowledge and tools to target the root causes of chronic diseases through modifications of risk factors steered by lifestyle choices. Since its inception, it has made substantial contributions to lifestyle medicine education, achieving over 1.2 million hours of training for healthcare professionals since 2004.

This study not only reinforces the feasibility of deprescribing medications in a primary care setting but also sheds light on the essential role of lifestyle medicine in chronic disease management. As healthcare evolves, initiatives like these highlight the need for a more holistic approach to patient care, merging medical treatment with lifestyle interventions for enhanced health outcomes.